Ask any Indian startup founder who has successfully raised a seed round what happens next, and the answer will almost universally involve the word ‘hard.’ Not hard as in competitive — hard as in structurally broken. Between the point at which a company has achieved product-market fit, built a small team, and generated its first meaningful revenue, and the point at which it is large enough to attract the attention of established late-stage growth funds and international VCs, lies a funding gap that has quietly killed hundreds of promising Indian companies over the past decade.
Ashish Dave, former CEO of Mirae Asset Venture Investments India, spent a decade watching companies fall into this gap. This week, he launched Sanskrit Capital, a new growth-stage fund targeting Rs 1,000 crore, to address it directly. Dave’s experience managing one of India’s most active early-stage funds gives him a rare X-ray view of which companies in this segment have genuine structural advantages versus which ones are burning cash on growth with no path to profitability.
The choice of ‘Sanskrit’ as a fund name is not accidental or merely evocative. Sanskrit — the foundational language of Indian civilisation — carries connotations of precision, depth, and structural integrity. Dave is signalling that Sanskrit Capital will be a conviction-based, concentrated fund: making 15 to 20 investments across the Rs 1,000 crore corpus rather than the 50 to 100 investments that more diversified funds tend to make. Each investment will be followed with active support: board representation where appropriate, access to Dave’s extensive network, and a commitment to holding through the messy middle phase of company building.
The fund’s timing is exceptional. India’s startup ecosystem is at a point of genuine maturation, and the mid-stage segment is where that maturation is most visible. Companies that were seeded during the 2019–2022 funding boom — thousands of startups in B2B SaaS, agri-tech, health-tech, fintech, and climate — are now hitting the inflection points at which they need growth capital. Companies that survived the funding winter of 2023–2024 with tighter unit economics and more defensible market positions represent exactly the kind of vintage a patient growth fund should target.





